news | MaaT Pharma

Press Releases

MaaT Pharma Expands Patent Portfolio with Three Granted Patents Covering its Microbiome Restoration Biotherapeutic Platform

- First patents to cover the fundamental processes for accessing the human gut microbiome as…

mrossettiMay 21, 2019

Press Releases

IMM-ETG – A New European Initiative for Intestinal Microbiome Medicinal Products

“Caelus Health, EnteroBiotix, Ferring Pharmaceuticals, and MaaT Pharma, in coordination with the Pharmabiotic Research Institute…

mrossettiMay 21, 2019

Press Releases

MaaT Pharma Announces Second Positive DSMB Safety Assessment of Phase II HERACLES Study in Acute GvHD

MaaT Pharma Announces Second Positive DSMB Safety Assessment of Phase II HERACLES Study in Acute…

mrossettiApril 9, 2019

Posters

HERACLES: A Phase II single-arm prospective study to assess the efficacy of Fecal Microbiota Transfer (FMT) in the treatment of steroid-refractory gastro-intestinal predominant aGVHD post allo-hsct

mrossettiMarch 26, 2019

Media

MaaT Pharma Presents Positive Phase 1b/2a Study Results in Acute Myeloid Leukemia Patients

mrossettiFebruary 6, 2019

Press Releases

MaaT Pharma Announces Positive DSMB Safety Review and Continuation of its Phase II HERACLES Study in Acute GvHD

Independent Data Safety Monitoring Board (DSMB) recommends to continue HERACLES study without modification. Lyon, France,…

mrossettiFebruary 5, 2019

Media

No Guts, No Glory: How Microbiome Research is Changing Medicine

mrossettiJanuary 23, 2019

Media

Gut bacteria could combat obesity and depression

mrossettiJanuary 17, 2019

Media

ASH readout a curtain raiser for Maat Pharma’s main act

mrossettiDecember 6, 2018

Media

Microbiome Therapy Shows Early Promise in Cancer Patients

mrossettiDecember 5, 2018

NextPrevious »

MaaT Pharma Expands Patent Portfolio with Three Granted Patents Covering its Microbiome Restoration Biotherapeutic Platform

IMM-ETG – A New European Initiative for Intestinal Microbiome Medicinal Products

MaaT Pharma Announces Second Positive DSMB Safety Assessment of Phase II HERACLES Study in Acute GvHD

HERACLES: A Phase II single-arm prospective study to assess the efficacy of Fecal Microbiota Transfer (FMT) in the treatment of steroid-refractory gastro-intestinal predominant aGVHD post allo-hsct

MaaT Pharma Presents Positive Phase 1b/2a Study Results in Acute Myeloid Leukemia Patients

MaaT Pharma Announces Positive DSMB Safety Review and Continuation of its Phase II HERACLES Study in Acute GvHD

No Guts, No Glory: How Microbiome Research is Changing Medicine

Gut bacteria could combat obesity and depression

ASH readout a curtain raiser for Maat Pharma’s main act

Microbiome Therapy Shows Early Promise in Cancer Patients

Categories

MAAT PHARMA

COMPANY

RESSOURCES

CONTACT